Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Cost of product sales (excluding amortization of acquired developed technologies) | 134.1 | 104.6 |
| Selling, general and administrative | 352.7 | 514.0 |
| Research and development | 196.0 | 180.7 |
| Intangible asset amortization | 172.3 | 154.4 |
| Gain on sale of priority review voucher | (122.8) | — |
| Total operating expenses | 732.3 | 953.7 |
| Income (loss) from operations | 336.6 | (55.9) |
| Interest expense, net | (39.9) | (53.7) |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's D&A?
- Jazz Pharmaceuticals (JAZZ) reported D&A of $172.3M in Q1 2026.
- How has Jazz Pharmaceuticals's D&A changed year-over-year?
- Jazz Pharmaceuticals's D&A increased by 11.6% year-over-year, from $154.4M to $172.3M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Jazz Pharmaceuticals's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude